Liu J.,Chaoyan Sanhuan Cancer Hospital |
Cui C.,Cancer Hospital and Institute |
Wang J.,Cancer Hospital and Institute |
Zhang Y.,Chaoyan Sanhuan Cancer Hospital |
And 7 more authors.
Chinese Journal of Clinical Oncology | Year: 2014
Objective: This study aims to determine the efficacy of chemotherapy and to identify potential chemotherapy agents for advanced primary duodenal carcinoma (PDC). Methods: Fifty-six patients with advanced PDC, who did and did not receive chemotherapy, were involved in this study. Response rates (RR), disease control rates (DCR), progression-free survival (PFS), and overall survival (OS) were analyzed. Results: The overall RR and DCR of 43 patients were 19.04% and 71.42%, respectively. The patients who received chemotherapy agents fluorourzcil and oxaliplatin exhibited higher RR compared with patients who received other chemotherapy combinations (35.29% vs. 7.69%, P=0.010 9). Palliative chemotherapy improved the OS of patients with advanced PDC compared with patients who did not receive chemotherapy (13.35 months vs. 5.65 months, HR=0.203, 95% CI: 0.083 to 0.497, P=0.000 5). Compared with the use of other chemotherapy regimens, treatment with a fluorourzcil-based chemotherapy agent resulted in a longer PFS (5.08 months vs. 1.08 months, HR=0.004, 95% CI:0.000 to 0.315, P=0.013 2). Multivariate analysis indicated mucinous histology and lymph mode metastasis as factors predictive of poor prognosis in patients with advanced PDC. Conclusion: Palliative chemotherapy may improve the OS of patients with advanced PDC. Source